Reviva Pharmaceuticals Hldg Inc (RVPH)

$0.36 -0.41 (-53.12%)
Market Cap 35.70M
Revenue (ttm) 0.00
Net Income (ttm) -29.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,446,500
Avg Vol 965,480
Day's Range N/A - N/A
Shares Out 46.74M
Stochastic %K 11%
Beta 0.11
Analysts Strong Sell
Price Target $9.43

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology
Sector: Healthcare
Phone: 408-501-8881
Fax: 408-904-6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
azonic
azonic Jun. 27 at 1:38 PM
$RVPH whos adding? Seems under valued now.
0 · Reply
BioAB
BioAB Jun. 27 at 12:12 PM
$RVPH I’m looking to finally add here.
1 · Reply
G101SPM
G101SPM Jun. 27 at 12:00 PM
$RVPH $0.38 ask. BUY/50X ADD TO LONG POSITION carries SPM 81.02 tag to $3.00 EXIT from $5.00 EXIT. DAC (dollar average cost includes this BUY). (60) $0.65.
0 · Reply
suhhhhh
suhhhhh Jun. 27 at 11:29 AM
$RVPH SEC Rule 415(a)(6) and General Instruction I.B.6 of Form S-3, the company cannot issue more than one-third of its total market capitalization within 12 months. With current shares totaling 46.74 million, adding 20 million shares already exceeds the 1/3 threshold. Their offering is violating SEC rule. to stop or cancel offering, I request you to submit complains on SEC homepage. https://www.sec.gov/submit-tip-or-complaint/report-problem-investment-account-or-financial-professional
0 · Reply
stazzy
stazzy Jun. 27 at 3:24 AM
$RVPH who would be stupid enough to buy the financing for common shares plus warrants for 50 cents when you can buy this garbage right now for commons for 35 cents and warrants at 3 cents.
1 · Reply
DistributionEquity
DistributionEquity Jun. 27 at 1:49 AM
$RVPH 23.5M market cap for a company with an exceptional, novel, potentially 'best in class' p3 asset, huge and expandable TAM, and comparables being acquired for billions of dollars? Stop yer cryin, and start yer buyin. Long, strong and brilaxin' on!
3 · Reply
Bucky712
Bucky712 Jun. 26 at 11:58 PM
$RVPH Big runner tomorrow and into next week
0 · Reply
Toni19
Toni19 Jun. 26 at 11:36 PM
$RVPH Not bad for a After Hour!https://www.marketwatch.com/investing/stock/rvph
0 · Reply
yellowdog11
yellowdog11 Jun. 26 at 11:10 PM
$RVPH In this situation if they do a reverse split doesn't really matter if the drug makes it to market phase If they say get 4 billion on a buyout if they have 500 million shares or do a 10/1 split for example so their are 50 million shares out which either way on a buyout still figures out to 8 bucks a share I think 500 million shares fully diluted should be enough to get this to market if they don't get bought out before that
2 · Reply
upanddown12311
upanddown12311 Jun. 26 at 9:26 PM
$RVPH warrants and offering = RS
0 · Reply
Latest News on RVPH
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 26, 2025, 8:40 AM EDT - 1 day ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Jun 25, 2025, 4:17 PM EDT - 1 day ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:00 AM EDT - 22 days ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Jun 2, 2025, 7:00 AM EDT - 25 days ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 4:05 PM EDT - 6 weeks ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Mar 30, 2025, 11:30 AM EDT - 3 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 5 months ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 5 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:00 AM EST - 6 months ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 6 months ago

Reviva Announces Proposed Public Offering

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Dec 11, 2024, 3:37 PM EST - 7 months ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 5:25 PM EST - 8 months ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Nov 6, 2024, 8:00 AM EST - 8 months ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 8 months ago

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:00 AM EDT - 9 months ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:30 AM EDT - 9 months ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Aug 21, 2024, 6:00 AM EDT - 11 months ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 14, 2024, 8:00 AM EDT - 1 year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Apr 15, 2024, 8:05 AM EDT - 1 year ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at the 36th Annual ROTH Conference

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 20, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Feb 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 25, 2024, 8:00 AM EST - 1 year ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 10, 2024, 8:00 AM EST - 1 year ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Jan 4, 2024, 8:00 AM EST - 1 year ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Dec 11, 2023, 8:00 AM EST - 1 year ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 4:05 PM EST - 1 year ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 20, 2023, 4:05 PM EST - 1 year ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 8:00 AM EST - 1 year ago

Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023, 4:01 PM EST - 1 year ago

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Nov 2, 2023, 3:11 AM EDT - 1 year ago

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Oct 30, 2023, 7:41 AM EDT - 1 year ago

Reviva Pharma's schizophrenia drug succeeds in late-stage study

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Oct 30, 2023, 7:30 AM EDT - 1 year ago

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Sep 29, 2023, 9:00 AM EDT - 1 year ago

Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

AREC STSS

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Sep 27, 2023, 2:48 AM EDT - 1 year ago

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

Sep 25, 2023, 6:00 AM EDT - 1 year ago

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Sep 22, 2023, 1:30 PM EDT - 1 year ago

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

azonic
azonic Jun. 27 at 1:38 PM
$RVPH whos adding? Seems under valued now.
0 · Reply
BioAB
BioAB Jun. 27 at 12:12 PM
$RVPH I’m looking to finally add here.
1 · Reply
G101SPM
G101SPM Jun. 27 at 12:00 PM
$RVPH $0.38 ask. BUY/50X ADD TO LONG POSITION carries SPM 81.02 tag to $3.00 EXIT from $5.00 EXIT. DAC (dollar average cost includes this BUY). (60) $0.65.
0 · Reply
suhhhhh
suhhhhh Jun. 27 at 11:29 AM
$RVPH SEC Rule 415(a)(6) and General Instruction I.B.6 of Form S-3, the company cannot issue more than one-third of its total market capitalization within 12 months. With current shares totaling 46.74 million, adding 20 million shares already exceeds the 1/3 threshold. Their offering is violating SEC rule. to stop or cancel offering, I request you to submit complains on SEC homepage. https://www.sec.gov/submit-tip-or-complaint/report-problem-investment-account-or-financial-professional
0 · Reply
stazzy
stazzy Jun. 27 at 3:24 AM
$RVPH who would be stupid enough to buy the financing for common shares plus warrants for 50 cents when you can buy this garbage right now for commons for 35 cents and warrants at 3 cents.
1 · Reply
DistributionEquity
DistributionEquity Jun. 27 at 1:49 AM
$RVPH 23.5M market cap for a company with an exceptional, novel, potentially 'best in class' p3 asset, huge and expandable TAM, and comparables being acquired for billions of dollars? Stop yer cryin, and start yer buyin. Long, strong and brilaxin' on!
3 · Reply
Bucky712
Bucky712 Jun. 26 at 11:58 PM
$RVPH Big runner tomorrow and into next week
0 · Reply
Toni19
Toni19 Jun. 26 at 11:36 PM
$RVPH Not bad for a After Hour!https://www.marketwatch.com/investing/stock/rvph
0 · Reply
yellowdog11
yellowdog11 Jun. 26 at 11:10 PM
$RVPH In this situation if they do a reverse split doesn't really matter if the drug makes it to market phase If they say get 4 billion on a buyout if they have 500 million shares or do a 10/1 split for example so their are 50 million shares out which either way on a buyout still figures out to 8 bucks a share I think 500 million shares fully diluted should be enough to get this to market if they don't get bought out before that
2 · Reply
upanddown12311
upanddown12311 Jun. 26 at 9:26 PM
$RVPH warrants and offering = RS
0 · Reply
MrAlientrader
MrAlientrader Jun. 26 at 9:25 PM
$RVPH offering is not a big issue. big discounted offering plus massive low priced warrants killed this stock.
0 · Reply
rocket_buddy
rocket_buddy Jun. 26 at 8:59 PM
$RVPH baby come back
0 · Reply
HjalmarTheGreat
HjalmarTheGreat Jun. 26 at 8:47 PM
$RVPH Wait, what?
0 · Reply
Bucky712
Bucky712 Jun. 26 at 8:46 PM
$RVPH Les Goh!
0 · Reply
azonic
azonic Jun. 26 at 8:22 PM
$RVPH offering at .5, price at .35… seems like a no brainer
0 · Reply
Compact12
Compact12 Jun. 26 at 8:00 PM
$RVPH so the offering is priced at 0.50 but the stock is trading at 0.35?
0 · Reply
Liondog
Liondog Jun. 26 at 7:45 PM
$RVPH have to ask yourself why would a institution put up 10m if they think this will be a failure
1 · Reply
TBCLLC23
TBCLLC23 Jun. 26 at 7:42 PM
We all knew this dilution was coming just to keep the lights on. Yeah, it sucks for us holders. But the data is solid, the science is real, and the odds of approval are still strong. Just gotta survive the float to reach the finish line. $RVPH 💊📉➡️📈
0 · Reply
yellowdog11
yellowdog11 Jun. 26 at 7:35 PM
$RVPH Like I said do you think a investment firm would put ten million unless they were optimistic about the company The 10 million will keep the ball moving forward for now and like I said even if they have to dilute the shares to 500 million once the drug is ready for market it will have a lot of value
0 · Reply
dcrown
dcrown Jun. 26 at 7:10 PM
$RVPH 10 mill won’t cover p3 ; just for administrative expenses ; go and figure it out
1 · Reply
yellowdog11
yellowdog11 Jun. 26 at 6:19 PM
$RVPH Lets say they have to dilute up to a os of 500 million shares to get the drug to market We know other schizo drugs have been bought out some before they were ready for market for between 8 billion to 15 billion So lets say this drug is as good as they say it is to me 4 billion would be low but with 500 million shares that is still 8 dollars per share
1 · Reply
yellowdog11
yellowdog11 Jun. 26 at 6:15 PM
$RVPH So people that think that the company is going under yet a investment firm is willing to invest 10 million in there company Doesn't seem logical to me The company investing would do their due diligence and would not put 10 million in if they didn't think they would succeed
1 · Reply